Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01171183 · ClinicalTrials.gov registry record · Phase 2
Carvedilol for Psychostimulant Dependence
A Phase 2 study of Cocaine Dependence and Cocaine Withdrawal, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT01171183: Completed Phase 2 study of Cocaine Dependence and Cocaine Withdrawal, sponsored by University of Arkansas.
NCT01171183 is a Phase 2 study of Cocaine Dependence and Cocaine Withdrawal that has completed, run by University of Arkansas. The registered enrollment target is 32 participants, below the 298-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01171183, a Phase 2 study of Cocaine Dependence and Cocaine Withdrawal, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This study examines whether carvedilol prolongs abstinence in recently abstinent cocaine dependent participants.
Primary Outcome
Treatment Effectiveness Score, defined by the # of cocaine negative urines during the outpatient phase of the study divided by the total number of urine samples (30) and then multiplied by 100.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG controlled release carvedilol
Study Locations (1)
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2010-08 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
What the finished NCT01171183 record still lists
NCT01171183 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 298-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Cocaine Dependence appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01171183 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT01171183 about?
NCT01171183 is a clinical study titled "Carvedilol for Psychostimulant Dependence". This study examines whether carvedilol prolongs abstinence in recently abstinent cocaine dependent participants.
What is the current status of trial NCT01171183?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2010-08. Estimated completion is 2014-05.
What conditions does trial NCT01171183 study?
This clinical trial studies the following conditions: Cocaine Dependence, Cocaine Withdrawal.
What interventions are being tested in trial NCT01171183?
The interventions under investigation include: Placebo (DRUG), controlled release carvedilol (DRUG).
Who is sponsoring clinical trial NCT01171183?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01171183 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01171183's enrollment target sits among peer trials
32 30th of 38 higher than 9 of 38 other Cocaine Dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cocaine Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clavulanic Acid for the Treatment of Cocaine Use Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Glutamatergic Modulation of Cocaine-related Deficits
COMPLETED · Phase 2
-
Disulfiram for Cocaine Abuse
COMPLETED · Phase 2
-
Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence
COMPLETED · Phase 2
-
Citalopram for Cocaine Dependence
COMPLETED · Phase 2
-
PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia